Wegovy’s Heart Benefits Boost Novo Nordisk’s Market Edge

New trial data reveals Wegovy’s edge in reducing heart risks, but can Novo Nordisk overcome U.S. market hurdles? Click to...

01/09/2025

2 views

Novo Nordisk Q2 2025: Sales Surge, Challenges Loom

Novo Nordisk's Q2 2025 earnings reveal a 13% sales jump, but a slashed outlook and new CEO spark debate. What's...

06/08/2025

3 views

Novo Nordisk’s shares tanked after a slashed forecast. Compounded GLP-1 drugs are eating into Wegovy’s market. Is this a dip...

29/07/2025

2 views

Novo Nordisk shares tanked 15% after slashing 2025 guidance. What's causing the dip in Wegovy and Ozempic sales? Dive into...

29/07/2025

3 views

Eli Lilly’s obesity drug Zepbound faces a CVS-Wegovy deal. Will it shake their market lead? Dive into the drama...

07/05/2025

0 views

Novo Nordisk slashes its 2025 forecast but surges 6.5% as it vows to crush copycat obesity drugs. Will Wegovy reclaim...

07/05/2025

0 views